Gaspaz DS Capsule is a combination pharmaceutical formulation containing Domperidone 10 mg and Omeprazole 20 mg, designed to manage gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort related to gastroparesis and functional dyspepsia. Omeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The synergistic action of these two agents in Gaspaz DS Capsule offers both symptomatic relief and addresses underlying pathophysiological mechanisms by reducing acid production and enhancing gastric motility. It is indicated for patients experiencing upper gastrointestinal symptoms such as heartburn, regurgitation, and delayed gastric emptying. Gaspaz DS should be used under medical supervision, considering contraindications such as hypersensitivity to components, and caution is advised in patients with cardiac arrhythmias or liver impairment. Adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Proper dosing and adherence to prescribed regimens are essential for optimal therapeutic outcomes.